Mental Health Impact of the COVID-19 Pandemic Among Migrants in Chile

Depression Clinical Trial

— STRING-COVID  

Official title:

Mental Health Impact of the COVID-19 Pandemic Among Immigrants in Santiago, Chile (STRING-COVID)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04497636
• Other study ID #: 170519004
• Status: Completed
• Start date: July 3, 2020
• Est. completion date: April 18, 2021

Study information

• Verified date: August 2020
• Source: Pontificia Universidad Catolica de Chile
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The mental health of a representative sample of immigrants residing in Santiago, Chile (STRING cohort) was assessed nine months prior to the COVID-19 pandemic (T0). Evidence suggests that social isolation affects mental health by increasing symptoms of anxiety and depression. One of the main components of the current COVID-19 pandemic is the social isolation imposed on the population. This study seeks to explore the short (T1) and long-term (T2) effects of the pandemic on the psychological wellbeing of the cohort. Specific aims are to 1. Describe the variations in the levels of mental health problems (i.e. symptoms of depression, anxiety, post-traumatic stress, sleep difficulties) and wellbeing of immigrants during the first (T1) and second follow-up (T2) 2. Calculate the short (T1) and long-term (T2) effects of social isolation on the levels of mental health problems of the immigrant population, and 3. Identify risk / protective factors associated with a short (T1) and long-term (T2) increase in mental health problems

Description:

Participants were interviewed at baseline (T0) 8 months before the COVID-19 pandemic. An online survey will be applied in two follow-up moments during the pandemic: 1. At 9 months (also 1 month after lockdown measures imposed) (T1) 2. At 18 months (also 10 months after lockdown measures imposed) (T2)

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1092
• Est. completion date: April 18, 2021
• Est. primary completion date: April 18, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Country of birth other than Chile
• Time since arrival to Chile: 3 months (at baseline)

Exclusion Criteria:

• Unable to understand Spanish

Related Conditions & MeSH terms

• Anxiety
• COVID-19
• Depression
• Loneliness
• Social Isolation
• Stress, Psychological

Locations

Country	Name	City	State
Chile	Pontificia Universidad Catolica de Chile	Santiago	RM

Sponsors (2)

Lead Sponsor	Collaborator
Pontificia Universidad Catolica de Chile	Fondo Nacional de Desarrollo Científico y Tecnológico, Chile

Country where clinical trial is conducted

Chile, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Depressive symptoms	The Patient Health Questionnaire 9 (PHQ-9; Kroenke, Spitzer & Williams, 2001) is used to measure symptoms of depression in accordance with the diagnostic criteria for major depressive disorder. The questionnaire consists of nine items scored on a four-point Likert scale (0-3), with the range of scores from 0 to 27. Higher scores indicate greater depression severity, and scores above 10 are considered as the cut-off that indicate that the patient is within the depressive area. Specific cut-off for primary care samples in Chile have been found yielding a cut-off of 7 and above for high sensitivity and specificity (Saldivia, Aslan, Cova, Vicente, Inostroza & Rincón, 2019).; Changes in depressive symptoms between baseline (T0) and two follow-up points (T1 and T2) will be assessed.	Month 1 (T1) and month 10 (T2)
Primary	Symptoms of anxiety	The Generalized Anxiety Disorder 7 (GAD-7; Spitzer, Kroenke, Williams & Löwe, 2006) is used to measure symptoms of anxiety and worry. The questionnaire consists of seven items scored on a four-point Likert scale (0-3), with the scores ranging from 0 to 21. Specific cut-off for primary care samples in Spain have been found yielding a cut-off of 10 and above for high sensitivity and specificity (García-Campayo et al, 2010).; Changes in symptoms of anxiety between baseline (T0) and two follow-up points (T1 and T2) will be assessed.	Month 1 (T1) and month 10 (T2)
Secondary	Symptoms of post-traumatic stress disorder	The Impact of Events Scale (IES-R; Weiss & Marmar, 1997) is used to measure symptoms of post-traumatic stress disorder (PTSD). There scale consists of 22 questions which are scored on a five-point Likert scale (0=not at all, 1=a little bit, 2=moderately, 3=quite a bit, 4=extremely). There are three subscales (i.e., avoidance, intrusion, hyperarousal) and the sum of the three subscales scores comprise the total score. A total score =33 indicates the likely presence of PTSD using criteria from the Diagnostic Symptom Manual (DSM-IV).; Changes in symptoms of post-traumatic stress between the two follow-up points (T1 and T2) will be assessed.	Month 1 (T1) and month 10 (T2)
Secondary	Changes in sleep difficulties	The Insomnia Severity Index (ISI; Bastein CH, et al. 2001) is used to assess the nature, severity, and impact of sleep difficulties. The questionnaire consists of 7 items scored on a five-point Likert scale (0=no problem, 4=very severe problem) with scores ranging from 0 to 28.; Changes in symptoms sleep difficulties between the two follow-up points (T1 and T2) will be assessed.	Month 1 (T1) and month 10 (T2)
Secondary	Changes in hazardous and harmful alcohol drinking	Using the three-item Alcohol Use Disorders Identification Test (AUDIT-C). Changes in hazardous and harmful alcohol drinking between baseline (T0) and two follow-up points (T1 and T2) will be assessed.	Month 1 (T1) and month 10 (T2)
Secondary	Changes in loneliness	Using the three-item Revised UCLA Loneliness Scale. Scores range from 3 to 9 with higher scores indicating higher perceived loneliness.; Changes in perceived loneliness between the two follow-up points (T1 and T2) will be assessed.	Month 1 (T1) and month 10 (T2)
Secondary	Change in general physical and mental health	Change in general physical and mental health, self-rated, on a VAS scale from 0 to 100. Higher scores indicate worse self-reported health.; Changes in perceived general physical and mental health between the two follow-up points (T1 and T2) will be assessed.	Change from last 2 weeks before pandemic to month 1 (T1) and month 10 (T2)
Secondary	Change in mental health symptoms from last 2 weeks before the pandemic to the last 2 weeks during the COVID-19 pandemic at T1 and T2.	Change in visual analogue scale-assessed transdiagnostic measures across all psychiatric symptoms in the last 2 weeks compared to the last 2 weeks of "regular life" before the COVID-19 outbreak.	Change from last 2 weeks before pandemic to month 1 (T1) and to month 10 (T2).
Secondary	Change in mental health well-being from last 2 weeks before the pandemic to the last 2 weeks during the COVID-19 pandemic at T1 and T2.	Change in World Health Organization (WHO)-5 well-being in the last 2 weeks compared to the last 2 weeks of "regular life" before the COVID-19 outbreak.	Change from last 2 weeks before pandemic to month 1 (T1) and to month 10 (T2).